Targeting aerobic glycolysis via hexokinase 2 inhibition in Natural Killer T cell lymphomas

Research Project

Project/Area Number	23K07830
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 54010:Hematology and medical oncology-related
Research Institution	Kanazawa University
Principal Investigator	エスピノザホルヘルイス金沢大学, 保健学系, 准教授 (30621213)
Co-Investigator(Kenkyū-buntansha)	高見昭良愛知医科大学, 医学部, 教授 (80324078) 稲岡プレイアデス千春金沢大学, 保健学系, 助教 (90507386)
Project Period (FY)	2023-04-01 – 2026-03-31
Project Status	Granted (Fiscal Year 2023)
Budget Amount *help	¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000) Fiscal Year 2025: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2024: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2023: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Keywords	NK/T lymphoma / Aerobic glycolysis / Hexokinase 2 / Targeted cancer therapy / Epstein Barr Virus
Outline of Research at the Start	We will investigate: (A1) determine HK2 expression in NKTL tumors. (A2) characterize the effects of HK2 inhibition in NKTL in vitro and in vivo. (A3) identify molecular markers associated with HK2 expression in NKTL. (A4) finding new and selective HK2 inhibitors with therapeutic potential in NKTL.